Infusystems Holdings, Inc. · AMEX:INFU
Infusystems — InfuSystem Holdings — Investor Presentation (April 2020)
20 slides from Infusystems's investor presentation, Apr 9, 2020
Slide 1: InfuSystem Investor Presentation April 2020
CinfuSystem INFUSION MADE EASY* INVESTOR PRESENTATION April 2020 (NYSE American: INFU)
Slide 2: Forward-Looking Statement / Non-GAAP Measures
Forward-Looking Statement / Non-GAAP Measures Forward Looking Statement Certain statements contained inthis presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, ‘and Section 21€ ofthe Securities Exchange Act of 1934, as amended, suc
Slide 3: Quote from CEO Rich DiIorio: patient at the center
Slide 4: Services and Solutions Facilitating Outpatient Care
“Services and Solutions Facilitating Outpatient Care” Exceptional Services, Products and People improving access to quality medical equipment at more than 6,500 sites of care Providing “last mile” solution for DME manufacturers and healthcare providers; focus and scale to improve patient care while
Slide 5: InfuSystem Key Facts At-a-Glance
InfuSystem Key Facts At-a-Glance 33 Years [|1,000,000+} 94,000 In Business Total Patients Impacted DEVICES IN FLEET 8 out of 10 TopHospmais: 4 Nearly 675 Nationwide Third-Party Payer Contracts *Source: US News & World Report, Best Hospitals. uly 2019 o~ Safe. Smart. Trusted, (InfuSystem’
Slide 6: Two Proven Business Platforms
Two Proven Business Platforms DME SUPPORT SERVICES INTEGRATED THERAPY SERVICE Duplicable, lower margin, high turn model Unique, high margin, high service model (concierge services) (turnkey therapies) + supply medical equipment + Supply proprietary consumables + Equip/supplies logistics + Hospital/c
Slide 7: 2019 Revenue: $81.1 million by segment
i] di VOMIVAlly f 2019 Revenue: $81.1 million SALES BY SEGMENT ome s23.6m (36%) Ws + owe 1s: Integrated Therapy Solutions Segment [DME: Durable Medical Equipment Support Services Segment ‘SALES BY MARKET SEGMENT $14.3 (18%) Third Party Payor Rental Drect Payor Rental» Product Sales
Slide 8: Platforms Leveraged into Multiple Therapies
Platforms Leveraged into Multiple Therapies Future Growth From Market Share Gains and From Adding New Therapies DME SUPPORT SERVICES INTEGRATED THERAPY SERVICES Duplicable, lower margin, high turn model Unique, high margin, high service model (concierge services) (turnkey therapies) Home Héalth Care
Slide 9: Well-Diversified Payer Mix
Well-Diversified Payer Mix % Cash Collected by payer 2019 Commercial payer: 47.7% Private Pay 2.4% No single payer greater than 10.9% ee 100% Direct Customer Pay ~ 6500 Direct Pay Hospital and Alternate Site Customers | Hospital / Alternate sit Direct Pay 48.8% 1.1% Medicaid eThusted:
Slide 10: Mainstream Distribution Unique Clinic-to-Home
Mainstream Distribution Unique Clinic-to-Home + Deliver equipment and supplies + High Service/High Value “Turnkey” model + Order/delivery logistics + Limited services by design + Logistics manufacturer-to-clinic-to-patient + 24x7 nursing support + Standard direct (invoice) billing + Specialized 3° p
Slide 11: Competitive Advantages
Competitive Advantages Significant Barriers to Entry Based On Unique Focus, National Scale, and Established Payer Network Leveraging High-Service Orientation to Win Concierge Opportunities Over 6,500 customers, Complete coverage of North America ‘Nursing staff that provides continuous 24/7 support t
Slide 12: Oncology: Significant Market Share Gains
Oncology: Significant Market Share Gains | oncology Outpatient Clinies and Third-Party Payer Contracts aso ms onetey Outpt nes tesa Payer Contes "9202018 a management projection + 2018: Largest elastomeric provider + 2019: Largest market competitor exiting market subject to FDA recall Creating furth
Slide 13: Full Year Financial Results
Full Year Financial Results 2019 2018 Net Income (loss) (1)See Appendix A.
Slide 14: Financial Trend & Current Targets
Financial Trend & Current Targets Net Revenues") & AEBITDA”) Cash Flows from Operations sn00 ss ws 2008 00 ss50 sss a. ne sa ee sus ‘ ees |_| : ont an 2 _ sg I 258 00 sry . Pa » = = no rao | Fr2017 aoe FrROI9 #120208) 20162017 2018k 019A 2000 2. See Appendix 5._ Wie continue to prepare for potential
Slide 15: Driving Shareholder Value
Driving Shareholder Value fierce TET ay + Rich Diorio appointed CEO + INFU repurchases 14% of shares outstanding | + Highest close of $11.75 0n 2/19 ‘+ Heavier focusonfinancialanalytcs & value sore + Accelerate IR activities, represent company based upon centers + Significant market share gainsin on
Slide 16: Stock price and performance as of April 2020
As of April 6, 2019 STOCK Price | 52 week Range $9.58 $4.00 - $11.89 ENTERPRISE VALUE $228 Million Stock Performance * 2019:147% $3.44 December 31, 2018; $8.53 December 31, 2019 © LTM:97% $4.87 April 5, 2019; $9.58 April 6, 2020
Slide 17: Executive Team
Executive Team Richard Dilorio- President, Chief Executive Officer, and Director Joined Instr: 2008 Industry Experience: Pharmaceutical, Healthcare, Life Scences, Medical Device Barry Steele - Executive Vice President and Chief Financial Officer Joined Inusystem: 2020 Industry Experience: Automotive
Slide 18: Looking Ahead
Looking Ahead Focus on strategic offerings and long-term, sustainable growth opportunities “nan Talent New Growth Manufacturer Device Capital Acquisition Strategy Partnerships Utilization Allocation Attract & retain Leverage existing. Access to the latest ‘Smart device Maximize value the best talent
Slide 19: InfuSystem Holdings, Inc. IR Contact
InfuSystem Holdings, Inc. + IR Contact Info: + Joe Dorame, Managing Partner + Lytham Partners, LLC + 602-889-9700 + dorame@lythampartners.com
Slide 20: Appendix A — GAAP to NON-GAAP Reconciliation
Appendix A — GAAP to NON-GAAP Reconciliation [NEF INCOME 109) TO ADJUSTED EBITDA: “Tete Months Ended Smart. Trusted InfuSystem
InfuSystem Holdings — Investor Presentation (April 2020) on 6ix